Abstract
We modified amylin chemically by conjugating methoxyl polyethyleneglycol succinimidyl carbonate (mPEGSC) of varying molecular weights (1 kDa, 2 kDa and 5 kDa). The reaction occurred within a few minutes, resulting in at least four distinct PEGylated products. The reaction products were separated by reversed-phase chromatography and identified by mass-spectrometry. The monoPEGylated and diPEGylated amylin products were generated rapidly through conjugation to the two amino groups of the N-terminal lysine residue. Both PEGylated amylin products bound to the receptor activity-modifying protein 1 (RAMP1). Pharmacological evaluation by subcutaneous administration in mice of monoPEGylated and diPEGylated amylin obtained with mPEG-SC 5 kDa revealed that both compounds modulated glycemia for longer times than unmodified amylin. Collectively, these data demonstrate the potential of bioconjugation with mPEG for the design of amylin therapeutics with sustained action.
Keywords: Amylin, diabetes, glycemia, islet associated polypeptide, PEGylation.
Protein & Peptide Letters
Title:Amylin Conjugation with Methoxyl Polyethyleneglycol
Volume: 20 Issue: 11
Author(s): Mariana F. A. N. Guterres, Luiz Henrique Guerreiro, Bruno Melo-Ferreira, Luiza C. S. Erthal and Luís Maurício T. R. Lima
Affiliation:
Keywords: Amylin, diabetes, glycemia, islet associated polypeptide, PEGylation.
Abstract: We modified amylin chemically by conjugating methoxyl polyethyleneglycol succinimidyl carbonate (mPEGSC) of varying molecular weights (1 kDa, 2 kDa and 5 kDa). The reaction occurred within a few minutes, resulting in at least four distinct PEGylated products. The reaction products were separated by reversed-phase chromatography and identified by mass-spectrometry. The monoPEGylated and diPEGylated amylin products were generated rapidly through conjugation to the two amino groups of the N-terminal lysine residue. Both PEGylated amylin products bound to the receptor activity-modifying protein 1 (RAMP1). Pharmacological evaluation by subcutaneous administration in mice of monoPEGylated and diPEGylated amylin obtained with mPEG-SC 5 kDa revealed that both compounds modulated glycemia for longer times than unmodified amylin. Collectively, these data demonstrate the potential of bioconjugation with mPEG for the design of amylin therapeutics with sustained action.
Export Options
About this article
Cite this article as:
F. A. N. Guterres Mariana, Guerreiro Henrique Luiz, Melo-Ferreira Bruno, S. Erthal C. Luiza and T. R. Lima Maurício Luís, Amylin Conjugation with Methoxyl Polyethyleneglycol, Protein & Peptide Letters 2013; 20 (11) . https://dx.doi.org/10.2174/09298665113209990067
DOI https://dx.doi.org/10.2174/09298665113209990067 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Rosuvastatin, Pravastatin, and Atorvastatin for the Treatment of Hypercholesterolaemia in HIV-Infected Patients Receiving Protease Inhibitors
Current HIV Research Anticancer Effects of Ginsenoside Rh2: A Systematic Review
Current Molecular Pharmacology Melatonin as a Pleiotropic Molecule with Therapeutic Potential for Type 2 Diabetes and Cancer
Current Medicinal Chemistry What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
Current Vascular Pharmacology Relations of Magnesium Intake with Metabolic Risk Factors and Risks of Type 2 Diabetes, Hypertension, and Cardiovascular Disease: A Critical Appraisal
Current Nutrition & Food Science The New Perspectives on Genetic Studies of Type 2 Diabetes and Thyroid Diseases
Current Genomics Membrane Ion Channels and Diabetes
Current Pharmaceutical Design Perspectives in Therapeutic Innovation in Ocular Surface Disorders and Dry Eye Syndrome
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Neural Pathways and Neuropeptides Mediate the Therapeutic Actions of DPP IV Inhibitors in Type-2 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Uric acid and Metabolic Syndrome: What is the Relationship?
Current Rheumatology Reviews Pharmacological Management of Hypertension in the Elderly - Certitudes and Controversies
Current Pharmaceutical Design PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Genetic and Molecular Basis of QTL of Diabetes in Mouse: Genes and Polymorphisms
Current Genomics A Review on the Effects of New Anti-Diabetic Drugs on Platelet Function
Endocrine, Metabolic & Immune Disorders - Drug Targets (Pro)renin Receptor as a New Drug Target
Current Pharmaceutical Design Regulation of Mitochondrial Biogenesis in Metabolic Syndrome
Current Drug Targets Primary Prevention of Cardiovascular Risk in Octogenarians by Risk Factors Control
Current Hypertension Reviews Recent Advances in Liver X Receptor Biology and Chemistry
Current Topics in Medicinal Chemistry Controversies in Anticoagulant Therapy in Vitreo-Retinal Surgery
Current Pharmaceutical Design The Effects of Obesity on the Cerebral Vasculature
Current Vascular Pharmacology